Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 9Genitourinary 5Other hematologic neoplasm 3Gastrointestinal 2CNS 2Thoracic 1Plasma cell 1Myeloid 1Lymphoid 1

Conditions

Neoplasms 1Multiple Myeloma 1

Interventions

Dexamethasone 870Lenalidomide 456Bortezomib 454Cyclophosphamide 365Melphalan 271Calcium Dobesilate 262daratumumab 233pomalidomide 207carfilzomib 182fludarabine phosphate 140fludarabine 136Thalidomide 125Peripheral Blood Stem Cell Transplantation 119Filgrastim 114ixazomib 93Mycophenolic Acid 90Granulocyte Colony-Stimulating Factor 89Whole-Body Irradiation 87Busulfan 87dexamethasone acetate 86Tacrolimus 78dexamethasone 21-phosphate 74Cyclosporine 68isatuximab 67auricularum 67Prednisone 65elotuzumab 58belantamab mafodotin 56Antilymphocyte Serum 56Etoposide 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Protein Subunit Vaccines × Plasma cell × Clear all
NCT00162500 2010-11-10

A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies

Hadassah Medical Organization

Phase 2 Withdrawn
15 enrolled
Plasma cell

Multiple Myeloma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡